JAK Inhibitors Versus Biologic Disease-Modifying Antirheumatic Drugs: Which Is More Effective for Rheumatoid Arthritis Pain?
Abigail Weiland
Feinberg School of Medicine, Northwestern University, Chicago, Illinois
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorCorresponding Author
Yvonne C. Lee
Feinberg School of Medicine, Northwestern University, Chicago, Illinois
Address correspondence via email to Yvonne C. Lee, MD, MMSc, at [email protected].
Contribution: Conceptualization, Resources, Supervision, Writing - original draft, Writing - review & editing
Search for more papers by this authorAbigail Weiland
Feinberg School of Medicine, Northwestern University, Chicago, Illinois
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorCorresponding Author
Yvonne C. Lee
Feinberg School of Medicine, Northwestern University, Chicago, Illinois
Address correspondence via email to Yvonne C. Lee, MD, MMSc, at [email protected].
Contribution: Conceptualization, Resources, Supervision, Writing - original draft, Writing - review & editing
Search for more papers by this authorDr. Lee's work was supported by the NIH (grant K24-AR-080840).
Author disclosures are available at https://onlinelibrary.wiley.com/doi/10.1002/art.43026.
Supporting Information
| Filename | Description |
|---|---|
| art43026-sup-0001-Disclosureform.pdfPDF document, 198.2 KB | Disclosure Form |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Wohlfahrt A, Bingham CO, 3rd, Marder W, et al. Responsiveness of patient-reported outcomes measurement information system measures in rheumatoid arthritis patients starting or switching a disease-modifying antirheumatic drug. Arthritis Care Res (Hoboken) 2019; 71: 521–529.
- 2Murphy AE, Minhas D, Clauw DJ, et al. Identifying and managing nociplastic pain in individuals with rheumatic diseases: a narrative review. Arthritis Care Res (Hoboken) 2023; 75: 2215–2222.
- 3Lee YC, Lu B, Guan H, et al. Physician prescribing patterns and risk of future long-term opioid use among patients with rheumatoid arthritis: a prospective observational cohort study. Arthritis Rheumatol 2020; 72: 1082–1090.
- 4Makabe K, Okada H, Tachibana N, et al. Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons. Arthritis Res Ther 2024; 26: 121.
- 5Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017; 376: 652–662.
- 6Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019; 71: 1788–1800.
- 7Bergman M, Tundia N, Martin N, et al. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Res Ther 2022; 24: 155.
- 8Strand V, Mysler E, Moots RJ, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open 2019; 5:e001040.
- 9Dougados M, Taylor PC, Bingham CO, 3rd, et al. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open 2022; 8:e002478.
- 10Eberhard A, Di Giuseppe D, Askling J, et al. Effectivness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis. Arthritis Rheumatol 2024.
- 11Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004; 8: 283–291.
- 12Taylor PC, Lee YC, Fleischmann R, et al. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial. J Clin Med 2019; 8: 831.
- 13Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets-a focus on the JAK-STAT pathway. Pain Res Manag 2018; 2018:8564215.
- 14Bai Z, Bartelo N, Aslam M, et al. Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis. Sci Transl Med 2024; 16:eadk3506.
- 15Wandner LD, Domenichiello AF, Beierlein J, et al. NIH's helping to end addiction long-termSM initiative (NIH HEAL Initiative) clinical pain management common data element program. J Pain 2022; 23: 370–378.
Online Version of Record before inclusion in an issue
